Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...

Pills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy, will probably become ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...